Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
To observe the safety, tolerability and clinical effects of crizotinib combined with
etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT)
for patients with relapsed and refractory ALK-positive Anaplastic Large Cell Lymphoma.